These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 19464758)

  • 1. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
    Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
    Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?
    Krautwald M; Münch G
    Exp Gerontol; 2010 Oct; 45(10):744-51. PubMed ID: 20211718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.
    Lue LF; Walker DG; Brachova L; Beach TG; Rogers J; Schmidt AM; Stern DM; Yan SD
    Exp Neurol; 2001 Sep; 171(1):29-45. PubMed ID: 11520119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.
    Valente T; Gella A; Fernàndez-Busquets X; Unzeta M; Durany N
    Neurobiol Dis; 2010 Jan; 37(1):67-76. PubMed ID: 19778613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.
    Rahmadi A; Steiner N; Münch G
    Clin Chem Lab Med; 2011 Mar; 49(3):385-91. PubMed ID: 21275816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease.
    Maczurek A; Shanmugam K; Münch G
    Ann N Y Acad Sci; 2008 Apr; 1126():147-51. PubMed ID: 18448809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress in Alzheimer's disease hippocampus: a topographical study.
    Cruz-Sánchez FF; Gironès X; Ortega A; Alameda F; Lafuente JV
    J Neurol Sci; 2010 Dec; 299(1-2):163-7. PubMed ID: 20863531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.
    Yan SD; Chen X; Fu J; Chen M; Zhu H; Roher A; Slattery T; Zhao L; Nagashima M; Morser J; Migheli A; Nawroth P; Stern D; Schmidt AM
    Nature; 1996 Aug; 382(6593):685-91. PubMed ID: 8751438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
    Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
    Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
    Yan SF; D'Agati V; Schmidt AM; Ramasamy R
    Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
    Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
    Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease.
    Morcos M; Hutter H
    J Alzheimers Dis; 2009; 16(4):897-908. PubMed ID: 19387121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
    Lüth HJ; Ogunlade V; Kuhla B; Kientsch-Engel R; Stahl P; Webster J; Arendt T; Münch G
    Cereb Cortex; 2005 Feb; 15(2):211-20. PubMed ID: 15238435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis.
    Schmitt HP
    Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease.
    Kojro E; Postina R
    J Alzheimers Dis; 2009; 16(4):865-78. PubMed ID: 19387119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
    Schmidt AM; Sahagan B; Nelson RB; Selmer J; Rothlein R; Bell JM
    Curr Opin Investig Drugs; 2009 Jul; 10(7):672-80. PubMed ID: 19579173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.